The Technical Analyst
MediciNova Inc [MNOV]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
MediciNova Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $1.400
America/New_York / 19 apr 2024 @ 11:02
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 68.66 mill |
| EPS: | -0.170 |
| P/E: | -8.24 |
| Earnings Date: | May 10, 2024 |
| SharesOutstanding: | 49.05 mill |
| Avg Daily Volume: | 0.0516 mill |
| RATING 2024-04-18 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -8.24 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.40x |
| Company: PE -8.24 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.054 (-24.71%) $-0.346 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.326 - 1.474 ( +/- 5.29%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-09 | Obrien Geoffrey | Buy | 84 000 | Employee Stock Option (Right to Buy) |
| 2024-01-09 | Matsuda Kazuko | Buy | 157 500 | Employee Stock Option (Right to Buy) |
| 2024-01-09 | Iwaki Yuichi | Buy | 210 000 | Employee Stock Option (Right to Buy) |
| 2023-08-04 | Lemerond Nicole | Buy | 18 333 | Stock Option (Right to Buy) |
| 2023-08-04 | Lemerond Nicole | Buy | 0 |
| INSIDER POWER |
|---|
| 98.70 |
| Last 93 transactions |
| Buy: 6 161 551 | Sell: 1 269 768 |
Forecast:
12:41 - $1.415
Live Trading Signals (every 1 min)
Forecast
1: 11:11 - $1.397
Forecast 2: 12:01 - $1.405
Forecast 3: 12:41 - $1.415
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.400 (0.00% ) |
| Volume | 0.0059 mill |
| Avg. Vol. | 0.0516 mill |
| % of Avg. Vol | 11.39 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MNOV
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MNOV
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Latest Press Releases
2024-04-02 19:00:00 - Press Release
Medicinova Announces Abstract Regarding Results Of A Clinical Trial Of Mn-166 (ibudilast) In Glioblastoma Accepted For Presentation At The 2024 American Society Of Clinical Oncology Annual Meeting (2024 Asco)
La jolla, calif., april 02, 2024 (globe newswire) -- medicinova, inc., a biopharmaceutical company traded on the nasdaq global market (nasdaq:mnov) and the standard market of the tokyo stock exchange (code number: 4875), today announced that an abstract regarding results of a clinical trial of mn-166 (ibudilast) in glioblastoma (gbm) has been selected for an oral presentation at the american society of clinical oncology (2024 asco) annual meeting to be held may 31 – june 4, 2024 in chicago. the oral presentation will be presented by one of the investigators of this clinical trial, gilbert youssef, m.d., attending physician at harvard medical school, center for neuro-oncology at dana-farber cancer institute and brigham and women's hospital.
2024-03-26 19:00:00 - Press Release
Medicinova Receives A Notice Of Allowance For a New Patent Covering Mn-166 (ibudilast) For The Treatment Of Macular Injury In Japan
La jolla, calif., march 26, 2024 (globe newswire) -- medicinova, inc., a biopharmaceutical company traded on the nasdaq global market (nasdaq:mnov) and the standard market of the tokyo stock exchange (code number: 4875), today announced it has received a notice of allowance from the japan patent office for a pending patent application which covers mn-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis.
2024-03-20 19:00:00 - Press Release
Medicinova Announces Two Abstracts Regarding Mn-001 (tipelukast) And Mn-002 Accepted For Presentation At The 92nd Eas 2024 Congress, The Annual Meeting Of The European Atherosclerosis Society
La jolla, calif., march 20, 2024 (globe newswire) -- medicinova, inc., a biopharmaceutical company traded on the nasdaq global market (nasdaq:mnov) and the standard market of the tokyo stock exchange (code number: 4875), today announced that two abstracts entitled “ study protocol to evaluate mn-001's (tipelukast) efficacy, safety and tolerability in subjects with non-alcoholic fatty liver disease (nafld), hypertriglyceridemia (htg) and type-2 diabetes mellitus (t2dm )” and “ mn-002, the metabolite of mn-001(tipelukast) promotes macrophage cholesterol efflux ” have been accepted and selected for poster presentation at the 92nd european atherosclerosis society (eas) 2024 congress to be held may 26-29, 2024.
2024-03-12 06:30:00 - Press Release
Medicinova Announces New Data And Results Of Mn-166 (ibudilast) In Chlorine Gas-induced Acute Lung Injury Presented At The 63rd Annual Meeting Of The Society Of Toxicology
La jolla, calif., march 12, 2024 (globe newswire) -- medicinova, inc., a biopharmaceutical company traded on the nasdaq global market (nasdaq:mnov) and the standard market of the tokyo stock exchange (code number: 4875), today announced that medicinova's collaborator, perenlei enkhbaatar, md, phd, faha, professor, department of anesthesiology, director, translational intensive care unit, charles robert allen professor in anesthesiology, university of texas medical branch, presented new data and results of a nonclinical study evaluating mn-166 (ibudilast) in a chlorine gas-induced acute lung injury (ciali) model at the society of toxicology (sot) 63rd annual meeting and toxexpo in salt lake city, utah.
2024-01-17 06:00:00 - Press Release
Medicinova Receives A Notice Of Grant For A New Patent Covering Mn-166 (ibudilast) For The Treatment Of Macular Injury In China
La jolla, calif., jan. 17, 2024 (globe newswire) -- medicinova, inc., a biopharmaceutical company traded on the nasdaq global market (nasdaq:mnov) and the standard market of the tokyo stock exchange (code number: 4875), today announced it has received a notice of grant from the chinese patent office for a new patent which covers mn-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis.
Latest News
2023-08-16 10:15:46 - Proactive Investors
Medicinova stock up on European patent award
Medicinova Inc (NASDAQ:MNOV) stock started Wednesday on the front foot boosted by a patent award in Europe. The European Patent Office has given protection to the company's asset MN-001 (tipelukast) for the treatment of scleroderma and/or systemic sclerosis.
2022-09-15 19:00:00 - GlobeNewsWire
MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference
LA JOLLA, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will be conducting one-on-one virtual meetings with institutional investors as part of the Lytham Partners Fall 2022 Investor Conference. The event is taking place virtually on September 28 - 29, 2022.
2022-06-08 09:15:02 - Benzinga
MediciNova Posts Promising Data From COVID-19 Treatment Candidate
MediciNova Inc (NASDAQ: MNOV) says the Phase 2 trial of MN-166 (ibudilast) in hospitalized COVID-19 patients demonstrated significant improvements compared to placebo for all four clinical endpoints analyzed. The trial achieved statistical significance for one of the co-.
2022-04-08 09:47:04 - Benzinga
MediciNova's Alcohol Use Disorder Candidate Reduces Alcohol Craving, Odds Of Heavy Drinking
MediciNova Inc (NASDAQ: MNOV) announced that secondary analysis of the Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD) was published in the journal Alcoholism: Clinical and Experimental Research. The publication describes a secondary analysis of a two-week clinical.
2021-11-23 11:20:59 - Pulse2
MediciNova (MNOV) Stock: Why The Price Jumped Today
The stock price of MediciNova, Inc. (NASDAQ: MNOV) increased by over 11% during intraday trading. This is why it happened.
2021-09-02 23:00:00 - GlobeNewsWire
MediciNova to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
LA JOLLA, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will participate in the virtual Morgan Stanley 19th Annual Global Healthcare Conference which will be held from September 9 - 15, 2021. Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O'Brien, JD/MBA, Vice President and Executive Officer, will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through Morgan Stanley.
2021-09-01 06:30:00 - GlobeNewsWire
MediciNova Announces MN-001 (tipelukast) Abstract regarding Lipid Metabolism in NASH/NAFLD Accepted for Presentation at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases
LA JOLLA, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced an abstract entitled “Improvement of Intracellular Lipid Metabolism by Tipelukast in the Pathogenesis of NASH/NAFLD" has been selected for poster presentation at The Liver Meeting® 2021, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) to be held November 12 - 15, 2021. MediciNova's research collaborator, Dr. Masatsune Ogura, Associate Professor at the Department of General Medical Science, Chiba University Graduate School of Medicine, will present the results of the study...
2021-08-30 06:30:00 - GlobeNewsWire
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND
LA JOLLA, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding MediciNova's ongoing Phase 2b/3 clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) has been accepted for presentation at the 32nd International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease) to be held virtually on December 7 - 10, 2021.
2021-08-12 19:00:00 - GlobeNewsWire
MediciNova Reports Second Quarter 2021 Financial Results and Business Update
Initiated preclinical animal studies for MN-166 as a treatment for chlorine gas-induced induced lung disease under partnership with BARDA
2021-07-06 06:30:00 - GlobeNewsWire
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Ophthalmic Disease
LA JOLLA, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of ophthalmic disease.